A giant mystery in giant cell myocarditis: navigating diagnosis, immunosuppression, and mechanical circulatory support [PDF]
ESC Heart Failure, 2020 Giant cell myocarditis is a rare but often devastating diagnosis. Advances in cardiac imaging and mechanical circulatory support have led to earlier and more frequent diagnoses and successful management. This disease state has wide variation in acuity of
Julianne M. Fallon +3 more
doaj +2 more sources
Proc (Bayl Univ Med Cent), 2021 Giant cell myocarditis (GCM) usually affects previously healthy adults and is a rapidly progressive and frequently fatal disease. It has a median survival of 3 months to death or transplant without appropriate therapy. Hence, early diagnosis is critical, with evidence showing rapidly instituted cyclosporine-based immunosuppression can improve ...
Gadela NV +3 more
europepmc +5 more sources
A giant and rapid myocardial remodeling due to fatal giant cell myocarditis: a case report [PDF]
Frontiers in Cardiovascular MedicineGiant cell myocarditis is a rare and rapidly progressive disease with a high mortality rate. We present the case of a 21-year-old male without a medical history who presented with a giant left ventricle (9.9 cm, EF:10%) and in a severe clinical state ...
Wei Zhang, Wei Zhang, Tao Guo, Tao Guo
doaj +2 more sources
Cardiac sarcoidosis and giant cell myocarditis after COVID‐19 infection [PDF]
ESC Heart Failure, 2022 Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19.
Entela Bollano +6 more
doaj +2 more sources
Fulminant Giant Cell Myocarditis following Heterologous Vaccination of ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19 [PDF]
Medicina, 2022 A 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19.
Dong-Hoon Kang +14 more
doaj +2 more sources
Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms [PDF]
Frontiers in Cardiovascular Medicine, 2021 The advent of immune checkpoint inhibitors (ICIs) has revolutionized the field of oncology, but these are associated with immune related adverse events.
Rishi Rikhi +11 more
doaj +2 more sources
Inhibition of NETosis via PAD4 alleviated inflammation in giant cell myocarditis [PDF]
iScience, 2023 Summary: Giant cell myocarditis (GCM) is a rare, usually rapidly progressive, and potentially fatal disease. Detailed inflammatory responses remain unknown, in particular the formation of multinucleate giant cells. We performed single-cell RNA sequencing
Zhan Hu +8 more
doaj +2 more sources
Giant Cell Myocarditis Presenting With Cardiogenic Shock [PDF]
JACC: Case ReportsGiant cell myocarditis (GCM) is a rare but often fatal inflammatory cardiomyopathy characterized by aggressive myocardial inflammation and necrosis. Prompt recognition and immunosuppressive therapy are critical for improving outcomes. A 48-year-old woman
Stefano H. Byer, MD, MS +7 more
doaj +2 more sources
Giant cell myocarditis following COVID‐19 successfully treated by immunosuppressive therapy [PDF]
Clinical Case Reports, 2022 It has been shown that severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), by coronavirus disease 2019 (COVID‐19), can lead to multi‐organ impairment including cardiac involvement and immunological problems.
Afsaneh Amiri +5 more
doaj +2 more sources